Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 4/20 | 0.62 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.62 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.54 |
| ▸ | NEK2 | P51955 | 1/20 | 0.54 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.54 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.54 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | EP300 | Q09472 | 1/20 | 0.47 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.47 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29862158 | 1.00 | CYP1A2 (0.62) | CYP1A2CYP2A6CHEK1NEK2LIMK1 | |
| SCHEMBL8720110 | 0.87 | CHEK1 (0.65) | CYP1A2CHEK1NEK2LIMK1DYRK1A | |
| SCHEMBL29862285 | 0.86 | CYP1A2 (0.62) | CYP1A2CYP2A6CHEK1NEK2LIMK1 | |
| SCHEMBL1755244 | 0.86 | CYP1A2 (0.62) | CYP1A2CYP2A6CHEK1NEK2LIMK1 | |
| SCHEMBL424167 | 0.79 | CYP1A2 (1.00) | CYP1A2CYP2A6CA2ALDH1A1TDP1 | |
| SCHEMBL29463284 | 0.79 | CYP1A2 (1.00) | CYP1A2CYP2A6CA2ALDH1A1TDP1 | |
| SCHEMBL14959260 | 0.79 | CYP1A2 (0.52) | CYP1A2CYP2A6CHEK1NEK2LIMK1 | |
| SCHEMBL29862298 | 0.77 | MEN1 (0.47) | CYP1A2CYP2A6CHEK1NEK2LIMK1 | |
| SCHEMBL8990307 | 0.76 | CHEK1 (0.73) | CYP1A2CHEK1NEK2LIMK1DYRK1A | |
| SCHEMBL29919884 | 0.76 | CHEK1 (0.73) | CYP1A2CHEK1NEK2LIMK1DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 177 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12510529-B2 | Method for determining authenticity and adulteration of marked petroleum hydrocarbons | SICPA HOLDING SA (CH) | 2025-12-30 | — | — | US | disclosed |
| EP-4069806-B1 | METHOD OF MARKING A PETROLEUM HYDROCARBON | SICPA HOLDING SA (CH) | 2025-04-16 | — | — | EP | disclosed |
| US-20240327736-A1 | METHOD OF MARKING A PETROLEUM HYDROCARBON | SICPA HOLDING SA (CH) | 2024-10-03 | — | — | US | disclosed |
| US-12031098-B2 | Method of marking a petroleum hydrocarbon | SICPA HOLDING SA (CH) | 2024-07-09 | — | — | US | disclosed |
| US-20230312498-A1 | NON-ATP/CATALYTIC SITE p38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS | UNIVERSITY OF MARYLAND, BALTIMORE | 2023-10-05 | — | — | US | disclosed |
| EP-4069807-B1 | METHOD FOR DETERMINING AUTHENTICITY AND ADULTERATION OF MARKED PETROLEUM HYDROCARBONS | SICPA HOLDING SA (CH) | 2023-10-04 | — | — | EP | disclosed |
| EP-3469088-B1 | BIOCATALYSTS AND METHODS FOR HYDROXYLATION OF CHEMICAL COMPOUNDS | CODEXIS INC (US) | 2023-09-06 | — | — | EP | disclosed |
| US-11718595-B2 | Non-ATP/catalytic site p38 Mitogen Activated Protein Kinase inhibitors | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2023-08-08 | — | — | US | disclosed |
| US-20230140941-A1 | NON-ATP/CATALYTIC SITE P38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2023-05-11 | — | — | US | disclosed |
| US-20230103579-A1 | METHOD FOR DETERMINING AUTHENTICITY AND ADULTERATION OF MARKED PETROLEUM HYDROCARBONS | SICPA HOLDING SA (CH) | 2023-04-06 | — | — | US | disclosed |
| US-7173035-B2 | Arylsulfonamide compounds | BIOVITRUM AB (SE) | 2007-02-06 | — | — | US | disclosed |
| US-7173035-B2 | Arylsulfonamide compounds | BIOVITRUM AB (SE) | 2007-02-06 | — | — | US | disclosed |
| US-7169925-B2 | Indole derivatives as interleukin-4 gene expression inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2007-01-30 | — | — | US | disclosed |
| US-7169925-B2 | Indole derivatives as interleukin-4 gene expression inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2007-01-30 | — | — | US | disclosed |
| US-7166603-B2 | Dihydropyrimidone inhibitors of calcium channel function | BRISTOL-MYERS SQUIBB CO. (US) | 2007-01-23 | — | — | US | disclosed |
| US-20070009597-A1 | Active substance combination comprising a compound with npy receptor affinity and a compound with 5-ht6 receptor affinity | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2007-01-11 | — | — | US | disclosed |
| US-7157454-B2 | Derivatives of n-(arylsulfonyl)beta-aminoacids comprising a substituted aminomethyl group, the preparation method thereof and the pharmaceutical compositions containing same | SANOFI-AVENTIS (FR) | 2007-01-02 | — | — | US | disclosed |
| US-7157454-B2 | Derivatives of n-(arylsulfonyl)beta-aminoacids comprising a substituted aminomethyl group, the preparation method thereof and the pharmaceutical compositions containing same | SANOFI-AVENTIS (FR) | 2007-01-02 | — | — | US | disclosed |
| WO-2006097293-A2 | COMBINATION OF A STEROID SULFATASE INHIBITOR AND AN ASCOMYCIN | NOVARTIS AG (CH) | 2006-09-21 | — | — | WO | disclosed |
| WO-2005009392-A2 | DIHYDROPYRIMIDONE INHIBITORS OF CALCIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230140941-A1 | NON-ATP/CATALYTIC SITE P38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS | MAPK1, MAPK8, MAPK4 | CYP1A2 3599/4885CYP2A6 3683/4885CHEK1 688/4885 |
| US-20230312498-A1 | NON-ATP/CATALYTIC SITE p38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS | MAPK1, MAPK8, MAPK4 | CYP1A2 3491/4885CYP2A6 4026/4885CHEK1 639/4885 |
| US-12510529-B2 | Method for determining authenticity and adulteration of marked petroleum hydrocarbons | CYP4A11, CYP11B1, CYP11A1 | CYP1A2 57/4885CYP2A6 75/4885CHEK1 3332/4885 |
| US-11718595-B2 | Non-ATP/catalytic site p38 Mitogen Activated Protein Kinase inhibitors | MAPK1, MAPK8, MAPK4 | CYP1A2 3491/4885CYP2A6 4026/4885CHEK1 639/4885 |
| US-20070009597-A1 | Active substance combination comprising a compound with npy receptor affinity and a compound with 5-ht6 receptor affinity | NPY5R, HTR6, NPY2R | CYP1A2 3453/4885CYP2A6 1150/4885CHEK1 4861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.